Summary & Overview
HCPCS J9394: Fulvestrant (Fresenius Kabi) 25 mg Injection
HCPCS Level II code J9394 designates a 25 mg injection of fulvestrant (Fresenius Kabi) that is not therapeutically equivalent to J9395. This injectable oncology agent is used in cancer care pathways where specific branded or manufacturer formulations must be identified for billing and supply tracking. Nationally, accurate coding for injectable oncologics matters for clinical documentation, payer adjudication, and drug utilization tracking.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of coding context, common sites of service, and the clinical framing of fulvestrant as an injectable antineoplastic/antihormonal agent. The publication also outlines benchmarks and billing considerations relevant to hospitals and outpatient infusion centers, including payer coverage patterns and typical claims workflows.
The content provides: a concise clinical description tied to the HCPCS Level II code, the expected service setting, and what to expect in payer interactions at a national level. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J9394 represents an injection of fulvestrant (Fresenius Kabi), listed as not therapeutically equivalent to J9395, at a 25 mg dosage. This code identifies the specific biologic oncology drug formulation supplied for administration.
-
Service type: Parenteral drug administration (injectable antineoplastic/antihormonal agent)
-
Typical site of service: Hospital outpatient departments, oncology infusion centers, and ambulatory infusion clinics
Clinical & Coding Specifications
Clinical Context
A typical patient is a postmenopausal woman with hormone receptor–positive, metastatic or locally advanced estrogen receptor–positive breast cancer who requires endocrine therapy after progression on prior anti-estrogen agents. The patient presents to an oncology infusion clinic for administration of intramuscular fulvestrant, billed with J9394 (fulvestrant, 25 mg, specific manufacturer not therapeutically equivalent to J9395). Clinical workflow: the medical oncologist documents indication, prior therapy, and weight/administration instructions in the electronic medical record; the oncology nurse verifies allergies, obtains informed consent for medication administration, confirms appropriate lab results (if required), and prepares the dose per pharmacy. Pharmacy dispenses the single-use prefilled syringe or vial labeled with J9394, and the nurse administers the intramuscular injection (usually into the gluteal muscle) while monitoring the patient for immediate adverse reactions for 15–30 minutes. Documentation includes the drug name and manufacturer, NDC, dose (number of 25 mg units billed), lot number, site of injection, route, date/time, and any concurrent medications or supportive care. Billing uses J9394 with appropriate diagnosis linkage to the oncology indication and may append a modifier if applicable (e.g., JW for discarded drug, QX for CRNA service under qualified supervision). Typical site of service is an outpatient hospital infusion center, physician office infusion suite, or freestanding oncology clinic. Payors commonly involved include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare for coverage and claims processing.